Omics underpins novel clues on VDR chemoprevention target in breast cancer

Paola Muti, Barbara Benassi, Elisabetta Falvo, Raffaela Santoro, Sergio Galanti, Gennaro Citro, Giuseppe Carrubba, Giovanni Blandino, Sabrina Strano

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Breast cancer is the commonest form of female malignancy among women in Western countries. The advent of genomic technologies has enhanced the diagnosis and the biological classification of such pathology. It has been demonstrated that cancer takes many years to be fully established. This long dormancy could represent a potential window for intervening with chemoprevention studies. Cancer chemoprevention is by definition the use of natural, synthetic, or biological chemical agents to reverse, suppress, or delay the genetic or other alterations that culminate in the appearance of the tumor phenotype. An important step for the success of chemoprevention is the identification of molecularly targeted agents to prevent cancer development. Currently, only two chemoprevention agents, raloxifene and tamoxifen, are used in clinical practice to prevent breast cancer. In this review, we will mainly focus on: (1) the application of genomic technologies for the identification and validation of molecular targets for chemoprevention; (2) the role of vitamin D and its cognate receptor VDR (vitamin D receptor) as a model for the molecularly targeted chemoprevention of breast cancer.

Original languageEnglish
Pages (from-to)337-346
Number of pages10
JournalOMICS A Journal of Integrative Biology
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Calcitriol Receptors
Chemoprevention
Breast Neoplasms
Neoplasms
Technology
Ergocalciferols
Biological Factors
Pathology
Tamoxifen
Vitamin D
Tumors
Phenotype

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Omics underpins novel clues on VDR chemoprevention target in breast cancer. / Muti, Paola; Benassi, Barbara; Falvo, Elisabetta; Santoro, Raffaela; Galanti, Sergio; Citro, Gennaro; Carrubba, Giuseppe; Blandino, Giovanni; Strano, Sabrina.

In: OMICS A Journal of Integrative Biology, Vol. 15, No. 6, 01.06.2011, p. 337-346.

Research output: Contribution to journalArticle

Muti, P, Benassi, B, Falvo, E, Santoro, R, Galanti, S, Citro, G, Carrubba, G, Blandino, G & Strano, S 2011, 'Omics underpins novel clues on VDR chemoprevention target in breast cancer', OMICS A Journal of Integrative Biology, vol. 15, no. 6, pp. 337-346. https://doi.org/10.1089/omi.2010.0086
Muti, Paola ; Benassi, Barbara ; Falvo, Elisabetta ; Santoro, Raffaela ; Galanti, Sergio ; Citro, Gennaro ; Carrubba, Giuseppe ; Blandino, Giovanni ; Strano, Sabrina. / Omics underpins novel clues on VDR chemoprevention target in breast cancer. In: OMICS A Journal of Integrative Biology. 2011 ; Vol. 15, No. 6. pp. 337-346.
@article{4877378ce850426a89d696a15beccb53,
title = "Omics underpins novel clues on VDR chemoprevention target in breast cancer",
abstract = "Breast cancer is the commonest form of female malignancy among women in Western countries. The advent of genomic technologies has enhanced the diagnosis and the biological classification of such pathology. It has been demonstrated that cancer takes many years to be fully established. This long dormancy could represent a potential window for intervening with chemoprevention studies. Cancer chemoprevention is by definition the use of natural, synthetic, or biological chemical agents to reverse, suppress, or delay the genetic or other alterations that culminate in the appearance of the tumor phenotype. An important step for the success of chemoprevention is the identification of molecularly targeted agents to prevent cancer development. Currently, only two chemoprevention agents, raloxifene and tamoxifen, are used in clinical practice to prevent breast cancer. In this review, we will mainly focus on: (1) the application of genomic technologies for the identification and validation of molecular targets for chemoprevention; (2) the role of vitamin D and its cognate receptor VDR (vitamin D receptor) as a model for the molecularly targeted chemoprevention of breast cancer.",
author = "Paola Muti and Barbara Benassi and Elisabetta Falvo and Raffaela Santoro and Sergio Galanti and Gennaro Citro and Giuseppe Carrubba and Giovanni Blandino and Sabrina Strano",
year = "2011",
month = "6",
day = "1",
doi = "10.1089/omi.2010.0086",
language = "English",
volume = "15",
pages = "337--346",
journal = "OMICS A Journal of Integrative Biology",
issn = "1536-2310",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Omics underpins novel clues on VDR chemoprevention target in breast cancer

AU - Muti, Paola

AU - Benassi, Barbara

AU - Falvo, Elisabetta

AU - Santoro, Raffaela

AU - Galanti, Sergio

AU - Citro, Gennaro

AU - Carrubba, Giuseppe

AU - Blandino, Giovanni

AU - Strano, Sabrina

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Breast cancer is the commonest form of female malignancy among women in Western countries. The advent of genomic technologies has enhanced the diagnosis and the biological classification of such pathology. It has been demonstrated that cancer takes many years to be fully established. This long dormancy could represent a potential window for intervening with chemoprevention studies. Cancer chemoprevention is by definition the use of natural, synthetic, or biological chemical agents to reverse, suppress, or delay the genetic or other alterations that culminate in the appearance of the tumor phenotype. An important step for the success of chemoprevention is the identification of molecularly targeted agents to prevent cancer development. Currently, only two chemoprevention agents, raloxifene and tamoxifen, are used in clinical practice to prevent breast cancer. In this review, we will mainly focus on: (1) the application of genomic technologies for the identification and validation of molecular targets for chemoprevention; (2) the role of vitamin D and its cognate receptor VDR (vitamin D receptor) as a model for the molecularly targeted chemoprevention of breast cancer.

AB - Breast cancer is the commonest form of female malignancy among women in Western countries. The advent of genomic technologies has enhanced the diagnosis and the biological classification of such pathology. It has been demonstrated that cancer takes many years to be fully established. This long dormancy could represent a potential window for intervening with chemoprevention studies. Cancer chemoprevention is by definition the use of natural, synthetic, or biological chemical agents to reverse, suppress, or delay the genetic or other alterations that culminate in the appearance of the tumor phenotype. An important step for the success of chemoprevention is the identification of molecularly targeted agents to prevent cancer development. Currently, only two chemoprevention agents, raloxifene and tamoxifen, are used in clinical practice to prevent breast cancer. In this review, we will mainly focus on: (1) the application of genomic technologies for the identification and validation of molecular targets for chemoprevention; (2) the role of vitamin D and its cognate receptor VDR (vitamin D receptor) as a model for the molecularly targeted chemoprevention of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79958712172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958712172&partnerID=8YFLogxK

U2 - 10.1089/omi.2010.0086

DO - 10.1089/omi.2010.0086

M3 - Article

C2 - 21348760

AN - SCOPUS:79958712172

VL - 15

SP - 337

EP - 346

JO - OMICS A Journal of Integrative Biology

JF - OMICS A Journal of Integrative Biology

SN - 1536-2310

IS - 6

ER -